Stem cells

Stem cells
#Biologics / Biotechnology #Immunology / Virology & Vaccines #Narrated podcasts #Stem cells

Is customisation healthcare’s secret weapon? 

This is the latest episode of the free narrated DDW podcast, “Is customisation healthcare’s secret weapon?”. It covers two narrated articles written for Volume 22, Issue 3 – Summer 2021 of DDW. The articles are called “Optimising vaccine production through… Read More

#Podcasts

#Autoimmune disease #iPSC #Stem cells

New human beta cell model enables discoveries in diabetes research 

Human Cell Design, a biotechnology company focused on generating translational human cellular models, has launched Endoc-BH5 to “open up entirely new scientific avenues in diabetes studies”, the company says.   What is Endoc-BH5?  Human Cell Design combined hiPSC-derived differentiated cells (human-induced Pluripotent Stem Cells) and primary… Read More

#News

#Drug discovery #iPSC #Stem cells #Therapeutics

Therapeutics research partnership to access induced Pluripotent Stem Cells 

Bone Therapeutics and Implant Therapeutics have signed a research evaluation agreement to enable Bone Therapeutics to access, evaluate and materially transfer Implant Therapeutics’ Induced Pluripotent Stem Cell (iPSC) lines, media, differentiation protocols and expertise.  Bone Therapeutics has developed a bone marrow-derived off-the-shelf, allogeneic MSC cell therapy platform. Read More

#News

#Cell therapy #Clinical trials #Covid-19 #Drug development #Drug discovery #Drug targets #Stem cells #Therapeutics

Exploring iPSCs for individual and population health applications

Listen to this article on the DDW Podcast: Brad Hamilton, Founder and Chief Science Officer at GoodCell examines the potential of induced Pluripotent Stem Cells. Across the world, patients suffering from heart failure, donor organ rejection and many other life-altering illnesses are struggling to combat the symptoms of their conditions. What… Read More

#Editor's Choice #Exclusive Content #News

#Biologics / Biotechnology #CAR-T #Cell therapy #Immunotherapy #Stem cells

Biotech’s pursuit of next-generation CAR-T

Listen to this article on the DDW Podcast: Pierre-Louis Joffrin leads Corporate Development at Mogrify. He examines immunotherapies including an assessment of the next generation of stem cell derived products. Biotech has joined the pursuit of next-generation CAR-Ts and it’s not subtle. Some new, others having pivoted towards the area, there… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News

Eye
#Biotechnology #Clinical trials #Drug development #Drug discovery #Stem cells

Dry Eye Syndrome drug candidate shows promise

BRIM Biotechnology has announced it is preparing to initiate Phase III trials in 2022 for BRIM421. BRIM421 is a first-in-class peptide derived from BRIM’s proprietary, stem cell regenerative, Short Peptide (PDSP) technology platform, which can also be applied across multiple therapy areas and indications. Data demonstrate the drug has the… Read More

#News

#Drug development #Drug discovery #Drug research #MS #Neuroscience #Stem cells

Mini 3-D brain models could speed up search for MS treatments

Tiny 3-D models that mimic vital aspects of the human nervous system have been developed in a step that could accelerate drug research for neurological conditions such as multiple sclerosis (MS). The millimetre-wide models – created using stem cells from human skin samples – will be… Read More

#News

#AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Gene therapy #Life sciences #Narrated podcasts #Stem cells

The power of precision and the potential of human tissue chips

Today’s episode is titled: The power of precision and the potential of human tissue chips, and covers 2 articles taken from the most recent issue of DDW. These articles are titled: The power of precision to keep biologics effective and safe & Why we should be interested in human tissue chips These… Read More

#Podcasts

#Gene editing #Stem cells

Single-cell cloning technology from iotaSciences at SLAS2021

iotaSciences, a company that develops technologies for single-cell cloning is giving exhibitor tutorials at SLAS2021 Digital. These tutorials will explore some of the key challenges of single-cell cloning for gene editing, stem cells and other applications. During the tutorials we will introduce our new cloning platform and provide customer data… Read More

#News

#Stem cells

REPROCELL launches personalised iPSC production service

REPROCELL’s new service – Personal iPS – will generate individual specific induced pluripotent stem cells (iPSC). The company will start taking orders from this month (January 2021) in Japan and has also launched a new B2C website to promote this service, which is currently only available in Japan. Personal iPS… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Animal models #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug repositioning #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #PCR #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Race To COVID-19 cure – the Core Model for solving the pandemic crisis (Part 1 & 2)

By Ibis Sanchez-Serrano and Rathnam Chaguturu Mitigation of COVID-19 pandemic requires a combination of effective epidemiological policies and the discovery/development of powerful drugs against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes this disease. This article examines the major initiatives being explored at the public policy level to… Read More

#Covid-19 #Exclusive Content

#Analysis #Biologics / Biotechnology #Business #Cell therapy #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #Immunology #In Silico Biology #Lead discovery #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Therapeutics

Will the next generation of CAR-T cells be modified using base editing?

By Dr Jamie Freeman Base editing is a potentially transformative technology for engineering DNA in cells that has the potential to generate knockouts or correct certain errors or mutations in the DNA for applications such as cell or gene therapies. Compared with currently-available gene editing methodologies such as CRISPR/Cas9, which… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Chemistry #Clinical specialities #Clinical trials #Genetics / genomes #High Content Screening #Immunology / Virology & Vaccines #Pathology #Preclinical #Stem cells #Target validation #Therapeutics

The COVID-19 race: how mouse models will help researchers cross the finish line

THE COVID-19 RACE how mouse models will help researchers cross the finish line By Dr Megan MacBride The emergence of SARS-CoV-2 virus and the disease it causes, COVID-19, have fuelled significant shifts in preclinical research across the globe. Amid the worldwide health emergency created by high infection rates, rapid transmission… Read More

#Covid-19 #Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Molecular medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

High content screening in action: a powerful tool to identify novel antivirals and vaccines

By Dr Karin Bottcher High content screening (HCS) has played a significant role in infectious disease research and drug discovery to date and can be a strong tool in the age of COVID-19 and beyond. With a focus on viral diseases, this article will describe how HCS has been used… Read More

#Covid-19 #Exclusive Content

#AI / data analytics / healthtech / informatics #Animal models #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Immunology / Virology & Vaccines #Molecular medicine #Precision medicine #Preclinical #Regenerative Medicine #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics

New manufacturing technologies make the promise of stem cell therapies a reality

By Dr Ross Macdonald Cell-based therapies are being widely recognised for their potential to treat a variety of medical conditions, but they face major obstacles toward commercialisation. Traditionally, they have been difficult and expensive to make in large quantities. Biopharmaceutical companies must develop manufacturing solutions that will enable them to… Read More

#Business & Investment #Covid-19 #Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Biomarkers #Cell therapy #Clinical trials #Drug development #Drug targets #Gene therapy #Immunology #Immunology / Virology & Vaccines #Molecular medicine #Oncology #Precision medicine #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #Therapeutics #Toxicology #Translational #Translational chemistry

Honing in on perfect targeting

Honing in on perfect targeting By Dr Samantha Zaroff Volume 21 Issue 3 - Summer 2020 The pros and cons of different delivery modalities for personalised cancer vaccines. Introducing neoantigens directly into a patient in order to elicit an anti-tumour killing immune response is known as personalised cancer vaccine therapy. Read More

#Exclusive Content